Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12MG)

What Is the Fragment 176-191 & CJC-1295 & Ipamorelin Blend and Why Buy It for Research?

Buy Fragment 176-191 & CJC-1295 & Ipamorelin Blend in Switzerland for research into lipid metabolism, growth hormone axis signaling, and integrated metabolic regulation. Specifically, this 12mg research formulation combines three complementary compounds in a single pre-mixed lyophilized vial: HGH Fragment 176-191 (4mg), CJC-1295 (Mod GRF 1-29, 4mg), and Ipamorelin (4mg). This triple blend pairs a lipolytic C-terminal hGH fragment with a GHRH analog and a selective growth hormone secretagogue (GHS) to probe convergent pathways in metabolism and GH-IGF-1 axis signaling.

HGH Fragment 176-191 is a synthetic 16-amino acid peptide corresponding to the C-terminal region of human growth hormone, specifically residues 176 through 191 of the full 191-amino acid hGH molecule. Professor Frank M. Ng and colleagues at Monash University identified this fragment as the minimal lipolytic domain of growth hormone through systematic structure-function mapping during the early 1990s. Furthermore, CJC-1295 (without DAC, also known as Modified GRF 1-29) is a synthetic 29-amino acid peptide analog of GHRH that activates the GHRH receptor on anterior pituitary somatotrophs, driving cAMP/PKA-mediated GH synthesis and secretion.

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that engages the GHS-R1a receptor through Gq/11-coupled signaling, mobilizing intracellular calcium to trigger GH granule release. Importantly, Ipamorelin is uniquely selective in its action—it stimulates GH release with negligible cortisol or prolactin elevation. Furthermore, Core Peptides supplies this blend as a lyophilized powder in a 12mg format exclusively for laboratory use. Therefore, researchers seeking to source this combination for their work will find it readily available when they buy Fragment 176-191 & CJC-1295 & Ipamorelin Blend in Switzerland.

Fragment 176-191 & CJC-1295 & Ipamorelin Blend Research Overview: Buy the Blend in Switzerland for Integrated Metabolic Studies

Centrally, research into this triple blend has focused on the complementary and potentially synergistic mechanisms of its three components. Each compound addresses a different aspect of metabolism and GH axis regulation:

• HGH Fragment 176-191 — A C-terminal fragment of human growth hormone that stimulates lipolysis (the breakdown of stored fat into free fatty acids) and inhibits lipogenesis (the conversion of glucose into fat), without the growth-promoting or insulin-desensitizing effects of full-length hGH.
• CJC-1295 (Mod GRF 1-29) — A GHRH analog that binds to the GHRH receptor on pituitary somatotrophs, driving GH synthesis and secretion through cAMP/PKA signaling, with a half-life of approximately 30 minutes.
• Ipamorelin — A selective ghrelin receptor agonist that triggers GH release through Gq/11-coupled signaling with negligible cortisol or prolactin elevation.

When combined, CJC-1295 sustains physiologic pulsatile GH secretion while Ipamorelin provides selective GH release, and Fragment 176-191 addresses lipid metabolism independently of GH signaling. This triple combination targets convergent but mechanistically independent pathways—GH synthesis (CJC-1295), GH release (Ipamorelin), and lipolysis (Fragment 176-191). Accordingly, researchers who buy Fragment 176-191 & CJC-1295 & Ipamorelin Blend in Switzerland from Core Peptides can support their investigations into integrated metabolic regulation, GH axis signaling, and lipid metabolism.

How Does the Fragment 176-191 & CJC-1295 & Ipamorelin Blend Work in Research?

Mechanistically, the Fragment 176-191, CJC-1295, and Ipamorelin blend operates through three complementary pathways that converge on metabolic regulation and GH axis signaling.

Lipolytic Pathway (HGH Fragment 176-191)

HGH Fragment 176-191 functions as the lipolytic domain of growth hormone, stimulating the breakdown of stored triglycerides into free fatty acids and glycerol. Studies have shown that Fragment 176-191 stimulates lipolysis and inhibits lipogenesis without the adverse effects on insulin sensitivity, blood glucose, cell proliferation, or muscle growth associated with full-length hGH. Furthermore, the peptide has demonstrated chronic weight loss in obese ob/ob mouse models.

GHRH Receptor Pathway (CJC-1295)

CJC-1295 activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, driving cAMP/PKA-mediated GH synthesis and secretion. The no-DAC variant (Mod GRF 1-29) has a half-life of approximately 30 minutes and mimics the natural, pulsatile release of GHRH. Importantly, this stimulation preserves the body’s natural pulsatile GH release pattern and negative feedback regulation through IGF-1 and somatostatin.

GHS-R1a Pathway (Ipamorelin)

Ipamorelin binds the growth hormone secretagogue receptor 1a (GHS-R1a), also known as the ghrelin receptor, through Gq/11-coupled signaling, mobilizing intracellular calcium to trigger GH granule release. Notably, Ipamorelin’s key distinguishing feature is its failure to significantly stimulate ACTH or cortisol release at GH-effective doses, suggesting preferential activation of specific downstream signaling branches. As a result, this selectivity makes Ipamorelin valuable for studies requiring isolated GH effects without adrenal axis activation.

Synergistic Integration

The triple combination provides integrated research coverage of lipid metabolism and the GH axis. CJC-1295 sustains physiologic pulsatile GH secretion while Ipamorelin provides selective GH release, and Fragment 176-191 addresses lipid metabolism independently. Additionally, the no-DAC variant of CJC-1295 is the typical pairing partner with Ipamorelin because its 30-minute half-life matches Ipamorelin’s roughly 2-hour half-life, which preserves a pulsatile pattern. Consequently, this integration allows researchers to study multiple facets of metabolic regulation within a single experimental system.

Why Is the Fragment 176-191 & CJC-1295 & Ipamorelin Blend Studied in Switzerland?

Primarily, researchers study this blend because it represents a well-characterized triple combination of complementary research compounds that enables investigation of lipid metabolism, GH axis signaling, and metabolic regulation simultaneously. In fact, this pre-mixed blend offers a practical way to study convergent metabolic and GH pathways without the need to source and reconstitute each compound separately.

Research has demonstrated the blend’s relevance across multiple domains. Fragment 176-191 has been studied for its lipolytic properties and potential applications in metabolic research, including a 2022 study demonstrating its ability to enhance the toxicity of doxorubicin-loaded nanoparticles against breast cancer cells. Additionally, CJC-1295 has been shown to stimulate the pituitary gland to release growth hormone. Furthermore, Ipamorelin has been characterized as a synthetic pentapeptide that activates the GHS-R1a receptor to stimulate pulsatile growth hormone release.

Furthermore, CJC-1295 combined with Ipamorelin has shown significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss. The CJC-1295 without DAC (Mod GRF 1-29) version has a half-life of about 30 minutes and mimics the natural, pulsatile release of GHRH. CJC-1295 without DAC is the typical pairing partner because its half-life matches Ipamorelin’s roughly 2-hour half-life, preserving a pulsatile pattern. Ultimately, researchers who buy Fragment 176-191 & CJC-1295 & Ipamorelin Blend in Switzerland gain access to a comprehensive research tool for investigating lipid metabolism, GH axis signaling, and metabolic regulation.

Fragment 176-191 & CJC-1295 & Ipamorelin Blend Research Areas in Laboratory Studies

Research Area	Focus	Key Components
Lipid Metabolism	Lipolysis stimulation, lipogenesis inhibition, fat oxidation	Fragment 176-191
GH Axis Signaling	GHRH receptor activation, GHS-R1a activation, pulsatile secretion	CJC-1295, Ipamorelin
Metabolic Regulation	Energy homeostasis, metabolic adaptation, integrated regulation	All three
Receptor Pharmacology	GHRH-R, GHS-R1a binding, biased agonism, receptor binding kinetics	CJC-1295, Ipamorelin
Selective GH Release	GH-specific effects, minimal cortisol/prolactin spillover	Ipamorelin
Pulsatile GH Secretion	Physiologic GH patterning, amplitude modulation, pulse dynamics	CJC-1295
Adipocyte Signaling	Fat breakdown, adipocyte function, lipid mobilization	Fragment 176-191

Fragment 176-191 & CJC-1295 & Ipamorelin Blend Compared With Related Research Formulations

Formulation	Components	Research Focus	Key Difference
Fragment 176-191 + CJC-1295 + Ipamorelin Blend	HGH Fragment 176-191 + CJC-1295 + Ipamorelin	Lipid metabolism, GH axis, metabolic regulation	Triple blend; adds Fragment 176-191 for lipolytic research
CJC-1295 + Ipamorelin Blend	CJC-1295 + Ipamorelin	GH release, metabolic regulation	Two-peptide blend; lacks Fragment 176-191 lipolytic component
Fragment 176-191 + AOD-9604	HGH Fragment 176-191 + AOD-9604	Lipid metabolism, lipolysis	Two-peptide blend; lacks GH axis components
Individual Components	Single compound only	Single pathway investigation	No multi-compound synergy or cross-pathway studies

Comparatively, this triple blend differs from other research formulations in its integrated approach to lipid metabolism and GH axis signaling. On the one hand, the CJC-1295 and Ipamorelin blend provides selective GH release with minimal cortisol elevation. On the other hand, adding Fragment 176-191 introduces lipolytic research capabilities that complement the GH axis effects of CJC-1295 and Ipamorelin. In contrast, formulations with only Fragment 176-191 and AOD-9604 focus exclusively on lipid metabolism without GH axis components.

Research Applications for the Fragment 176-191 & CJC-1295 & Ipamorelin Blend in Switzerland

Scientists have investigated this triple-peptide blend across several research domains:

• Lipid Metabolism Research: Researchers use Fragment 176-191 to study lipolysis stimulation, lipogenesis inhibition, and the molecular mechanisms underlying fat oxidation.
• GH Axis Signaling Research: CJC-1295 and Ipamorelin are employed to study GHRH receptor activation, GHS-R1a binding, and pulsatile GH secretion dynamics.
• Metabolic Regulation Studies: The blend is used to investigate integrated metabolic regulation, energy homeostasis, and metabolic adaptation pathways.
• Receptor Pharmacology: The blend serves as a tool for studying GHRH-R and GHS-R1a binding, receptor binding kinetics, and biased agonism.
• Selective GH Release Studies: Ipamorelin’s selective GH profile with minimal cortisol elevation is investigated in endocrine research.
• Pulsatile GH Secretion: CJC-1295’s pulsatile GH patterning is studied in models of physiologic GH secretion.

Evidently, researchers who buy Fragment 176-191 & CJC-1295 & Ipamorelin Blend in Switzerland gain a valuable addition to any laboratory toolkit focused on lipid metabolism, GH axis signaling, and metabolic research.

Fragment 176-191 & CJC-1295 & Ipamorelin Blend Product Specifications

Specification	Details
Product Name	Fragment 176-191 & CJC-1295 & Ipamorelin Blend
Alternative Names	HGH Fragment 176-191 + Mod GRF 1-29 + Ipamorelin, Triple GH/Metabolic Blend
Total Content	12mg
Composition	Fragment 176-191 4mg + CJC-1295 (Mod GRF 1-29) 4mg + Ipamorelin 4mg (1:1:1 ratio)
Form	Lyophilized powder
Purity	Not verified
Fragment 176-191 Sequence	YLRIVQCRSVEGSCGF (16 amino acids)
Fragment 176-191 Molecular Weight	1,817 Da (approx.)
Fragment 176-191 CAS Number	66004-57-7 (free base)
CJC-1295 Sequence	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
CJC-1295 Molecular Weight	3,367.9 Da
CJC-1295 CAS Number	863288-34-0
Ipamorelin Sequence	Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Ipamorelin Molecular Weight	711.9 Da
Ipamorelin CAS Number	170851-70-4
Research Category	Weight Management & Metabolism / Growth Hormone Peptides
Research Use	Laboratory research use only
CoA	Available upon request (not verified)
Storage	Lyophilized powder should be stored desiccated at -20°C or below, protected from light
Solubility	Soluble in water and bacteriostatic water; reconstitute slowly

How to Evaluate the Fragment 176-191 & CJC-1295 & Ipamorelin Blend Quality for Research

When sourcing this triple-peptide blend for laboratory research, researchers should consider several quality indicators:

• Identity Confirmation: Analytical techniques such as mass spectrometry should confirm the identity and molecular weight of each component peptide.
• Purity Assessment: High-performance liquid chromatography (HPLC) should verify purity of each peptide, with ≥98% considered standard for research-grade material.
• Batch Traceability: Lot numbers and batch information enable researchers to track specific production runs.
• Certificate of Analysis: A CoA should accompany the product, detailing analytical testing results for each component.
• Labeling Accuracy: Proper labeling should clearly indicate the product name, composition (4mg Fragment 176-191 + 4mg CJC-1295 + 4mg Ipamorelin), total content, and storage recommendations.
• Storage Conditions: Appropriate storage at -20°C or below in desiccated, dark conditions helps maintain peptide stability.

Understanding the Certificate of Analysis

Typically, a Certificate of Analysis (CoA) accompanies research peptide blends and provides information about the specific batch’s analytical testing. For example, a CoA may include product identity confirmation for each component, purity percentages as determined by HPLC, batch or lot number for traceability, analytical methods used (e.g., mass spectrometry, HPLC), and a physical description of the product.

Nevertheless, it is important to note that a CoA does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. Instead, it serves as a quality control document that helps researchers verify the identity and purity of the peptides they are using in their laboratory investigations.

Storage and Stability of the Fragment 176-191 & CJC-1295 & Ipamorelin Blend

Core Peptides supplies this blend as a lyophilized (freeze-dried) powder. To maintain stability and integrity:

• Store the lyophilized powder desiccated at -20°C or below for long-term storage
• Store at 4°C for short-term storage if frequent access is required
• Avoid repeated freeze-thaw cycles
• Reconstitute only immediately before use with appropriate sterile solvents (e.g., bacteriostatic water or sterile water)
• Inject solvent slowly against the inner wall of the vial rather than directly onto the powder; do not shake
• Gently roll the vial in a circular motion to dissolve
• Once reconstituted, refrigerate at 2°C to 8°C and utilize promptly
• Protect from light and moisture

Frequently Asked Questions About Buying the Fragment 176-191 & CJC-1295 & Ipamorelin Blend in Switzerland

What is the Fragment 176-191 & CJC-1295 & Ipamorelin Blend?

Specifically, this 12mg blend combines HGH Fragment 176-191 (4mg), CJC-1295 (Mod GRF 1-29, 4mg), and Ipamorelin (4mg) in a 1:1:1 ratio. It pairs a lipolytic hGH fragment with a GHRH analog and a selective GHS for integrated metabolic and GH axis research.

What is the blend researched for?

Primarily, researchers study this blend for its integrated effects on lipid metabolism, GH axis signaling, and metabolic regulation. It is most often discussed for lipolysis research, GH axis studies, and metabolic research.

How does the blend work?

Mechanistically, Fragment 176-191 stimulates lipolysis and inhibits lipogenesis; CJC-1295 activates the GHRH receptor on pituitary somatotrophs, driving GH synthesis; and Ipamorelin engages GHS-R1a, triggering selective GH release with negligible cortisol elevation. Consequently, the combination produces convergent effects on lipid metabolism and GH axis signaling.

What is the composition of the blend?

The blend contains Fragment 176-191 4mg, CJC-1295 (Mod GRF 1-29) 4mg, and Ipamorelin 4mg for a total of 12mg.

What is the amino acid sequence of Fragment 176-191?

The amino acid sequence is YLRIVQCRSVEGSCGF.

What is the amino acid sequence of CJC-1295?

CJC-1295 is a 29-amino acid peptide: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It selectively stimulates GH release with negligible cortisol or prolactin elevation.

How does Ipamorelin differ from other GHRPs?

Ipamorelin produces highly selective GH release with negligible cortisol or prolactin elevation, whereas other GHRPs such as GHRP-2, GHRP-6, and Hexarelin generate robust GH output alongside measurable increases in ACTH, cortisol, and prolactin.

What evidence exists for the blend?

The synergistic effect of combining GHRH analogs with GHSs is well-established in the literature. Fragment 176-191 has been studied for its lipolytic properties in preclinical models. Each peptide has been studied individually for its respective mechanisms. Published human evidence for the specific combination of CJC-1295 and Ipamorelin is lacking.

Is the blend approved as a medicine?

No. Regulatory authorities have not approved the blend as a medicine, pharmaceutical, or therapeutic agent. It is a research tool for laboratory use only.

Is the blend intended for human use?

No. The blend is intended for laboratory research use only and is not for human consumption, injection, or therapeutic application.

Where can I buy the Fragment 176-191 & CJC-1295 & Ipamorelin Blend in Switzerland?

You can buy the Fragment 176-191 & CJC-1295 & Ipamorelin Blend in Switzerland from Core Peptides, a trusted research peptide supplier serving the Swiss scientific community.

How should researchers evaluate the quality of this blend?

Researchers should look for identity confirmation via mass spectrometry for each component, purity data from HPLC, batch traceability, and a Certificate of Analysis.

Related Research Compounds

Researchers interested in the Fragment 176-191 & CJC-1295 & Ipamorelin Blend may also find the following related compounds relevant to their work:

• Fragment 176-191 — Individual hGH C-terminal fragment researched for lipolysis and lipid metabolism.
• CJC-1295 (Mod GRF 1-29) — Individual GHRH analog researched for GH synthesis and pulsatile secretion.
• Ipamorelin — Individual GHRP researched for selective GH release with minimal cortisol elevation.
• CJC-1295 & Ipamorelin Blend — Two-peptide GHRH/GHS blend with selective GH release.

Explore Weight Management & Metabolism

The Fragment 176-191 & CJC-1295 & Ipamorelin Blend belongs to the Weight Management & Metabolism category of research compounds. Weight Management & Metabolism products are studied for their potential roles in metabolic regulation, lipid metabolism, and energy homeostasis. Generally, researchers who buy this blend in Switzerland often pair it with related compounds in this category to explore complementary pathways in metabolic research and GH axis signaling.

Explore Growth Hormone Peptides

Researchers studying GH axis signaling, growth hormone secretagogues, and GHRH analogs may also find relevant compounds in the Growth Hormone Peptides category. The blend’s combination of GHRH and GHS pathways makes it a valuable tool for investigating receptor pharmacology and convergent GH signaling.

Further Research

For researchers seeking to deepen their understanding of the Fragment 176-191 & CJC-1295 & Ipamorelin Blend and its research applications, the following areas may warrant further investigation:

• The relationship between combined lipolytic and GH axis activity and specific downstream signaling pathways in different cell types
• Comparative studies between the triple blend and individual components in various metabolic and GH axis models
• The potential for Fragment 176-191’s lipolytic effects to complement GH-dependent anabolic signaling
• Mechanistic studies on peptide stability and compatibility in blended systems
• Exploration of the blend’s effects on different tissue systems beyond adipose and musculoskeletal models

Research Disclaimer

The Fragment 176-191 & CJC-1295 & Ipamorelin Blend is a research peptide formulation supplied for laboratory research use only. Researchers must not use it for human consumption, injection, or any form of therapeutic application. Moreover, this product is not a medicine, pharmaceutical, or medical device. Furthermore, Swissmedic, the FDA, EMA, or any other regulatory authority have not approved it for human use. Researchers should consult Swissmedic for applicable regulations and guidance on research peptide handling in Switzerland.

Generally, the information provided on this page is for educational and scientific reference purposes only. Therefore, it does not constitute medical advice, treatment recommendations, or dosing instructions. Ultimately, researchers bear the responsibility for ensuring that their use of this product complies with all applicable laws, regulations, and institutional guidelines.

Finally, all research involving peptide blends should be conducted by qualified personnel in appropriate laboratory settings with proper safety protocols.